Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy
- Conditions
- Diabetes Type 2
- First Posted Date
- 2007-04-24
- Last Posted Date
- 2007-11-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 24
- Registration Number
- NCT00464880
- Locations
- 🇩🇰
Novartis, Gentofte, Denmark
A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD)
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2020-12-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 501
- Registration Number
- NCT00463242
- Locations
- 🇵🇷
Novartis Investigative Site, Hato Rey, Puerto Rico
26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Pulmonary Disease, Chronic ObstructiveCOPDLung Diseases, Obstructive
- Interventions
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2011-08-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 2059
- Registration Number
- NCT00463567
- Locations
- 🇺🇸
Asthma & Allergy Research Associates, Dallas, Texas, United States
🇺🇸North Shore University Hospital, New Hyde Park, New York, United States
🇺🇸University of North Carolina, Chapel Hill, North Carolina, United States
Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-structure Infections
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2011-03-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 52
- Registration Number
- NCT00463801
- Locations
- 🇮🇹
Novartis Italy, Saronno, Italy
Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 Diabetes
- Conditions
- Diabetes Type 2
- First Posted Date
- 2007-04-17
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 18
- Registration Number
- NCT00461136
- Locations
- 🇩🇰
Novartis, Gentofte, Denmark
Efficacy of Formoterol vs Ipatropioum Bromide Plus Fenoterol in Children (5-<12 Years) With Acute Bronchial Obstruction
- Conditions
- Acute Bronchial Obstruction, Asthma
- Interventions
- Drug: fenoterol/ipratropium bromide
- First Posted Date
- 2007-04-16
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 60
- Registration Number
- NCT00460577
- Locations
- 🇻🇪
Novartis Investigator site - five sites in Caracas, Caracas, Venezuela
🇻🇪Novartis Investigator Site, Maracaibo, Venezuela
Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride Versus 5% Amorolfine Nail Lacquer in Patients With Mild to Moderate Toenail Onychomycosis
- Conditions
- Onychomycosis
- Interventions
- First Posted Date
- 2007-04-12
- Last Posted Date
- 2011-05-06
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1029
- Registration Number
- NCT00459537
- Locations
- 🇹🇷
Novartis Investigative Site, Various Cities, Turkey
Decongestant Effect, Timing of Effect and Impact on Sleep and General Well-Being of Xylometazoline in Subjects With a Common Cold
- Conditions
- Common Cold
- First Posted Date
- 2007-03-27
- Last Posted Date
- 2007-05-03
- Lead Sponsor
- Novartis
- Target Recruit Count
- 60
- Registration Number
- NCT00452270
- Locations
- 🇬🇧
Novartis Investigative Site, Cardiff, Wales, United Kingdom
Evaluation of Long-Term Immunogenicity in Children and Adolescents Boosted With a New Pediatric TBE Vaccine After Five Years
- Conditions
- Encephalitis, Tick-Borne
- First Posted Date
- 2007-03-27
- Last Posted Date
- 2008-04-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 235
- Registration Number
- NCT00452621
- Locations
- 🇩🇪
Center 11, Eberbach /Neckar, Germany
🇩🇪Center 16, Zirndorf, Germany
🇩🇪Center 1, Weilheim i. OB, Germany
A Comparison of Certoparin and Unfractionated Heparin in the Prevention of Thromboembolic Events in Acutely Ill Medical Patients
- First Posted Date
- 2007-03-23
- Last Posted Date
- 2012-07-25
- Lead Sponsor
- Novartis
- Target Recruit Count
- 3254
- Registration Number
- NCT00451412
- Locations
- 🇩🇪
Novartis investigative sites, Nürnberg, Germany